Global Lysosomal Acid Lipase Deficiency Treatment Market, By Treatment (Enzyme Replacement Therapy, Lipid Modifying Agents (Statins), Surgery, Supportive Care), Therapy Type (Liver Transplant, Hematopoietic Stem Cell Transplant), Indication (Wolman Disease, Cholesteryl Ester Storage Disease), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Lysosomal Acid Lipase Deficiency Treatment Market Analysis and Size
According to the National Institute for Health and Care Excellence (NICE) 2019, around 70% of individuals suffering from lysosomal acid lipase deficiencies risk developing liver problems and eventually requiring a liver transplant. Lysosomal acid lipase deficiency is a very rare disease and occurs in only about 1 out of 500,000 individuals, typically in newborn babies. Cholesterol Ester Storage Disease (CESD) is more predominant and often affects children and adolescents.
Data Bridge Market Research analyses a growth rate in the lysosomal acid lipase deficiency treatment market in the forecast period 2023-2030. The expected CAGR Lysosomal acid lipase deficiency treatment market is tend to be around 11.3% in the mentioned forecast period. The market was valued at USD 649.02 million in 2022, and it would grow upto USD 1528.34 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lysosomal Acid Lipase Deficiency Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Enzyme Replacement Therapy, Lipid Modifying Agents (Statins), Surgery, Supportive Care), Therapy Type (Liver Transplant, Hematopoietic Stem Cell Transplant), Indication (Wolman Disease, Cholesteryl Ester Storage Disease), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Alexion Pharmaceuticals, Inc (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Lonza (Switzerland), Thermo Fisher Scientific (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Lupin (India), Lannett (U.S.), Hetero Healthcare Limited. (India), Zydus Group (India), Sandoz International GmbH (Switzerland), BioCrick BioTech (China)
|
|
Market Opportunities
|
|
Market Definition
Lysosomal acid lipase deficiency is a rare genetic condition that can lead to extreme liver disease and sometimes gets difficult to diagnose. The disease is mostly caused by mutation in the lysosomal acid lipase (LIPA) gene which results in the accumulation of triglyceride and cholesteryl esters in different tissues of the human body. The primary symptoms include vomiting, diarrhoea, weight loss that eventually leads to malnutrition, hepatomegaly or even death.
Lysosomal Acid Lipase Deficiency Treatment Market Dynamics
Drivers
- Increasing FDA Approvals of Drugs
The rapid novel innovations, drug development, and research resulted in rapid drug approvals by several organizations such as the FDA and thus it led to the market growth. In 2015, FDA approved genetically modified organisms (GMO) chickens, for the increased production of a recombinant human lysosomal acid lipase (LAL) protein in their eggs that will be used for lysosomal acid lipase (LAL) deficiency treatment. The Europe commission in 2015 granted marketing permission of Kanuma, that can be used for the treatment of LAL deficiency for patients of all age groups, that is expected to boost the growth of kanuma in region.
- Growing Adoption of Enzyme Replacement Therapy
Among the different treatment types, enzyme replacement therapy is projected to increase the market growth during the forecast period, due to high efficacy and long-term disease control after treatment. Thus, it increases the growth of the market.
Opportunities
- Increasing Demand For Liver Transplant
As per the National Institute for Health and Care Excellence (NICE) 2016, around 50% of patients who are suffering from lysosomal acid lipase (LAL) deficiency have higher chances of liver complications, that includes cirrhosis or fibrosis and liver transplant. The growing incidences of liver complications due to LAL deficiency is projected to increase demand for liver transplants, boosting the growth of the LAL deficiency treatment market during the forecast period.
Restraints/Challenges
- Lack of Awareness
For many decades, this deficiency disease is not much known in several parts of the world. The appropriate treatment for the disease and its associated applications are unaware to the people. Thus, it hampers market growth.
- High Cost of Treatment Process
The enormous expenditure required for its treatment processes obstructs market growth. Numerous market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This lysosomal acid lipase deficiency treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lysosomal acid lipase deficiency treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Lysosomal Acid Lipase Deficiency Treatment Market Scope
The lysosomal acid lipase deficiency treatment market is segmented on the basis of treatment, therapy type, indication, end-user distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Enzyme Replacement Therapy
- Lipid Modifying Agents (Statins)
- Surgery
- Supportive Care
Therapy Type
- Liver Transplant
- Hematopoietic Stem Cell Transplant
Indication
- Wolman Disease
- Cholesteryl Ester Storage Disease
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Lysosomal Acid Lipase Deficiency Treatment Market Regional Analysis/Insights
The lysosomal acid lipase deficiency treatment market is analyzed and market size insights and trends are provided by treatment, therapy type, indication, end-user distribution channel as referenced above.
The major countries covered in the lysosomal acid lipase deficiency treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market due to the presence of key manufacturers of the product is high and, increasing research and development activities.
Asia-Pacific is considered to grow over the coming years due to increased new research and developments on lysosomal acid lipase deficiency treatment market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Lysosomal Acid Lipase Deficiency Treatment Market Share Analysis
The lysosomal acid lipase deficiency treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lysosomal acid lipase deficiency treatment market
Key players operating in the lysosomal acid lipase deficiency treatment market include:
- Alexion Pharmaceuticals, Inc (U.S)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- AstraZeneca (U.K.)
- Lonza (Switzerland)
- Thermo Fisher Scientific (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Lupin (India)
- Lannett (U.S.)
- Hetero Healthcare Limited. (India)
- Zydus Group (India)
- Sandoz International GmbH (Switzerland)
- BioCrick BioTech (China)
SKU-